|Bid||310.00 x 1200|
|Ask||322.50 x 200|
|Day's Range||315.05 - 332.65|
|52 Week Range||187.01 - 459.75|
|Beta (3Y Monthly)||1.91|
|PE Ratio (TTM)||76.81|
|Earnings Date||Jan 30, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||450.10|
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...
NEW YORK, Nov. 29, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
On November 26, Abiomed (ABMD) stock closed at $311.15, a ~3.92% rise from its previous day’s close of $299.41 on November 23. Abiomed stock rose from $187.41 at the close of market on December 29, 2017, to $311.15 at the close of market on November 26, 2018, reflecting a ~66% year-to-date rise.
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider ABIOMED (ABMD).
Medical technology stocks hit record highs in 2018 and three of the fastest-growing stocks among them have tacked on double-digit earnings growth for the past five years.
NEW YORK, NY / ACCESSWIRE / November 13, 2018 / It was a day of red for ReShape Lifesciences and ABIOMED on Monday. Both stocks had double digit losses despite encouraging developments reported. RDI Initiates ...
The medical device maker was the S&P 500’s best performer this year as of Friday’s close, notching gains in excess of 115 percent. While the results met the company’s primary target to advance the study into a pivotal trial, a broader drop in technology names, and what Goldman Sachs calls health-care’s “FAANG-Y” cohort, may be adding pressure to the stock after the less-than-stellar results. Shares of the medical device maker fell as much as 19 percent, the most intraday in more than three years while the S&P 500 Health Care Equipment Index was on track for its worst day since April.
Abiomed (ABMD) announces the results of the FDA STEMI Door-to-Unloading safety and feasibility randomized controlled trial, which show unloading the left ventricle with Impella CP® for 30 minutes prior to reperfusion in patients presenting with anterior ST-segment elevation myocardial infarction (STEMI) without cardiogenic shock is safe and feasible, when compared to Impella patients reperfused immediately.
Abiomed stock popped to a monthly high Wednesday after an analyst upgraded it ahead of a key presentation for its heart pump in heart-attack patients.